707
Participants
Start Date
September 12, 2019
Primary Completion Date
October 14, 2020
Study Completion Date
October 14, 2020
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine
Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine
Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
Meningococcal group C polysaccharide Conjugate vaccine adsorbed
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Investigational Site Number 2080002, Hvidovre
Investigational Site Number 2080003, Odense
Investigational Site Number 2080001, Aarhus
Investigational Site Number 2460002, Turku
Investigational Site Number 2760017, Hamburg
Investigational Site Number 2760013, Itzehoe
Investigational Site Number 2460003, Pori
Investigational Site Number 2460001, Tampere
Investigational Site Number 2760012, Wolfsburg
Investigational Site Number 2760003, Mönchengladbach
Investigational Site Number 2760005, Mönchengladbach
Investigational Site Number 2760004, Bramsche
Investigational Site Number 2760007, Hürth
Investigational Site Number 2460010, Seinäjoki
Investigational Site Number 2460008, Kokkola
Investigational Site Number 2760011, Mannheim
Investigational Site Number 2760008, Schwaigern
Investigational Site Number 2760015, Bönnigheim
Investigational Site Number 2760019, Bretten
Investigational Site Number 2760020, Herxheim
Investigational Site Number 2760009, Schweigen
Investigational Site Number 2760010, Tuttlingen
Investigational Site Number 2760006, Schönau
Investigational Site Number 2460007, Oulu
Investigational Site Number 2760018, Tauberbischofsheim
Investigational Site Number 2760002, Erfurt
Investigational Site Number 2460006, Espoo
Investigational Site Number 2460005, Helsinki
Investigational Site Number 2460004, Järvenpää
Sanofi Pasteur, a Sanofi Company
INDUSTRY